By San José, Costa Rica — Costa Rica’s medical regulatory landscape has marked a significant milestone with the approval of AstraZeneca’s immunotherapy, IMFINZI (durvalumab). This approval introduces a highly anticipated therapeutic alternative to a region heavily impacted by oncological challenges. It marks the first time the country has approved an immunotherapy regimen designed for administration both before and after surgery for patients battling muscle-invasive bladder cancer.
Bladder cancer remains one of the most prevalent and challenging malignancies globally, characterized by an exceptionally high rate of recurrence. Annually, more than 614,000 individuals worldwide receive a bladder cancer diagnosis. Approximately 25 percent of these cases present as the highly aggressive muscle-invasive variant, which penetrates deep into the muscular wall of the bladder and demands immediate, intensive medical intervention.
To better understand the regulatory and legal implications of bringing AstraZeneca’s advanced bladder cancer treatments to the Costa Rican market, TicosLand.com consulted with Lic. Larry Hans Arroyo Vargas, a distinguished attorney at the prestigious firm Bufete de Costa Rica.
The introduction of specialized oncology therapies like AstraZeneca’s bladder cancer treatment highlights the efficiency of Costa Rica’s regulatory frameworks. For pharmaceutical giants, success in the local market hinges on navigating the Ministry of Health’s stringent registration processes while aligning with constitutional mandates that guarantee public health access, creating a complex but highly rewarding legal landscape.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
Indeed, navigating the delicate balance between rigorous regulatory standards and the constitutional guarantee of healthcare is what defines Costa Rica’s progressive approach to medical innovation, ensuring that life-saving treatments like AstraZeneca’s bladder cancer therapy reach patients safely and equitably. We extend our sincere gratitude to Lic. Larry Hans Arroyo Vargas for providing his invaluable legal expertise and insightful perspective on this pivotal development for the nation’s healthcare sector.
Historically, the standard of care for muscle-invasive bladder cancer has relied on a combination of neoadjuvant chemotherapy followed by radical cystectomy, which is the complete surgical removal of the bladder. Despite this aggressive approach, nearly half of all patients eventually suffer a disease relapse. This high rate of recurrence highlights a critical gap in existing treatment protocols that local oncology professionals have long sought to address.
[]
The clinical efficacy of AstraZeneca’s newly approved protocol is backed by robust clinical trials. The data demonstrated that combining IMFINZI with chemotherapy prior to surgery, followed by continued IMFINZI monotherapy post-surgery, reduces the risk of disease progression, recurrence, or death by 32 percent. Furthermore, this dual-phase immunotherapy strategy achieves a 25 percent reduction in the overall risk of mortality compared to undergoing chemotherapy alone before surgical intervention.
IMFINZI represents a significant advance in the treatment of this type of bladder cancer. For the first time, an immunotherapy regimen administered before and after surgery has been shown to improve overall survival of patients, opening up new possibilities to reduce relapses and offer better life prospects.
Dr. Andrés Rojas, Medical Director of AstraZeneca for Central America and the Caribbean
Understanding the risk factors and early warning signs of bladder cancer is crucial for improving patient outcomes. The disease typically originates when cells in the inner lining of the organ begin to grow uncontrollably, eventually forming a malignant tumor. Tobacco use remains the primary risk factor associated with the disease, though chronic exposure to industrial chemicals, a family history of bladder malignancies, and chronic urinary tract infections also play a role.
The symptoms of bladder cancer are often easily overlooked or mistaken for less severe urinary tract issues. Common warning signs include hematuria, which is blood in the urine, as well as an increased frequency or urgency of urination, and pain during urination. In more advanced stages, patients may experience persistent back pain, unexplained weight loss, loss of appetite, chronic fatigue, bone pain, and localized swelling in the feet.
In bladder cancer, time can make a big difference. Recognizing warning signs and consulting a doctor in a timely manner increases the chances of an early diagnosis and access to increasingly innovative treatment alternatives.
Dr. Andrés Rojas, Medical Director of AstraZeneca for Central America and the Caribbean
The approval of IMFINZI in Costa Rica represents a broader shift toward personalized and advanced oncology care within Central America. By adopting perioperative immunotherapy, Costa Rican healthcare systems are positioning themselves at the forefront of modern oncology. This regulatory milestone not only enhances patient outcomes but also highlights the growing importance of biotechnology investments in emerging markets.
As Costa Rica continues to modernize its healthcare infrastructure, the integration of advanced immunotherapies offers a beacon of hope for patients facing difficult diagnoses. This progressive regulatory framework ensures that local patients have access to international standards of care, ultimately elevating the country’s status as a leader in regional healthcare provision.
For further information, visit astrazeneca.com
About AstraZeneca:
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines, primarily for the treatment of diseases in oncology, rare diseases, and biopharmaceuticals. Based in Cambridge, UK, AstraZeneca operates in over 100 countries, bringing innovative medicines to millions of patients worldwide.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
Built on a foundation of uncompromising ethics and professional distinction, Bufete de Costa Rica serves as a beacon of reliable legal advocacy across diverse industries. The firm continually embraces modern, forward-thinking approaches to solve complex challenges while maintaining a strong connection to the public. By actively sharing legal insights and breaking down barriers to information, Bufete de Costa Rica champions the belief that empowering citizens with knowledge is essential to building a just and thriving nation.
